Check Claims Before You Publish

Visual summary (metrics)

Key strengths (data-driven)

• Focus on experimental addiction neuroscience integrating behavioral models, molecular mechanisms, and translational genetics (e.g., circadian gene Per2 → glutamate → alcohol intake) Per2 → glutamate → alcohol (Nature Med)
• Authored/ co-authored methodological synthesis of behavioral assays in addiction (strongly cited review) advising multi-paradigm approaches and calling out methodological heterogeneity 2006 Addiction Biology review (methods)

Limitations, blindspots, and bias risks

Reproducibility & methodological rigor

Experimental strengths include use of cross-level assays (molecular, microdialysis, behavioral operant tests) and pharmacological reversal (acamprosate) which strengthen causal claims in animal models; weaknesses are small human sample sizes for genetic associations and the recognized variability of behavioral protocols across labs. See Per2 paper for direct multi-level data and effect sizes (EAAT1 protein reductions, ~3× extracellular glutamate, operant/self-administration differences) Per2 multi-level evidence

Concrete suggestions to improve scientific impact

• Replicate human PER2 associations in larger, multi-ethnic cohorts and provide functional assays (e.g., eQTL, allele-specific expression, reporter assays) to move beyond correlation.
• Deposit raw behavioral datasets and microdialysis traces with metadata (strain, sex, time-of-day) to improve reproducibility and allow re-analysis across labs.
• Adopt or lead community-standard protocols for key assays (operant schedules, ethanol concentrations, CPP paradigms) to reduce inter-lab heterogeneity highlighted in the 2006 review.
• Where possible, provide pre-registered analysis plans and share code for data processing (microdialysis quantification, operant-breakpoint calculations) to reduce analytic flexibility.

What would overturn the central experimental claims?

For the Per2→glutamate→alcohol model, falsifying evidence would include: (a) failure to replicate EAAT1 reductions and extracellular glutamate increase in independent Per2 mutant lines, (b) no difference in operant/voluntary ethanol intake under tightly controlled, pre-registered protocols, or (c) larger human cohorts showing no PER2 association or opposite effects. These specific negative outcomes would substantially weaken the proposed mechanistic link Per2 falsification criteria

Data & source list (key cited works)

• Per2 Nature Med (2004)
• 2006 Addiction Biology methods review
• 1999 Lancet commentary